[USA] ZIVO Bioscience, Inc. (OTCMKTS:ZIVO) a biotech/agtech R&D company engaged in the commercialization of nutritional and medicinal products derived from proprietary algal strains, announces today its largest shareholder, HEP Investments, LLC, (“HEP”) has extended the maturity on its Convertible Debt.
In a related filing, HEP has agreed to extend the maturity date on $16.7 million of its Secured Convertible Promissory Note, including all related interest payments, from September 30, 2018 to April 1, 2019.
ZIVO’s management and board of directors continue to take actions to improve its capital structure to support future strategic growth. “HEP Investments has been our largest shareholder for quite some time. We appreciate their support and their continued commitment to stand behind the Company,” states Andrew Dahl, President & CEO, ZIVO Bioscience, Inc.
HEP Investments managing member, Laith Yaldoo, adds “Today’s extension of our fund’s debt to April 1, 2019 is meant to signal to the management team at ZIVO, as well as other current and future stakeholders in the Company, of our long-term commitment to the ZIVO core business strategy. We are a fundamental shareholder and continue to support the steps taken towards commercialization and market entry.”
View original article at: Largest Shareholder of ZIVO Bioscience, Inc. to extend maturity date of its Convertible Debt
Contact Algae World News for algae industry advertising and other opinions: firstname.lastname@example.org